Gene · 9547
Papers2,447
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
881 to 900 of 2,447
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Establishment and validation of a novel immune-related prognostic signature in malignant pleural mesothelioma. | Ann Transl Med | 2022 | 35280360 | PubTator, text mining | PubMed |
| CXC Chemokine Signaling in Progression of Epithelial Ovarian Cancer: Theranostic Perspectives. | Int J Mol Sci | 2022 | 35269786 | PubTator, text mining | PubMed |
| Cancer Stem Cells in Ovarian Cancer-A Source of Tumor Success and a Challenging Target for Novel Therapies. | Int J Mol Sci | 2022 | 35269636 | PubTator, text mining | PubMed |
| Antrodia cinnamomea exerts an anti-hepatoma effect by targeting PI3K/AKT-mediated cell cycle progression in vitro and in vivo. | Acta Pharm Sin B | 2022 | 35256953 | PubTator, text mining | PubMed |
| Ample dietary fat reduced the risk of primary vesical calculi by inducing macrophages to engulf budding crystals in mice. | Acta Pharm Sin B | 2022 | 35256944 | PubTator, text mining | PubMed |
| Construction of a Redox-Related Prognostic Model with Predictive Value in Survival and Therapeutic Response for Patients with Lung Adenocarcinoma. | J Healthc Eng | 2022 | 35251577 | PubTator, text mining | PubMed |
| CBX4 Regulates Replicative Senescence of WI-38 Fibroblasts. | Oxid Med Cell Longev | 2022 | 35251476 | PubTator, text mining | PubMed |
| Insights Gained and Future Outlook From scRNAseq Studies in Autoimmune Rheumatic Diseases. | Front Immunol | 2022 | 35251048 | PubTator, text mining | PubMed |
| Prognostic Significance and Therapeutic Target of CXC Chemokines in the Microenvironment of Lung Adenocarcinoma. | Int J Gen Med | 2022 | 35250303 | PubTator, text mining | PubMed |
| Neoantigen Identification and Response to Adoptive Cell Transfer in Anti-PD-1 Naïve and Experienced Patients with Metastatic Melanoma. | Clin Cancer Res | 2022 | 35247926 | PubTator, text mining | PubMed |
| Human Endometrial Organoids: Recent Research Progress and Potential Applications. | Front Cell Dev Biol | 2022 | 35242764 | PubTator, text mining | PubMed |
| Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma. | Cell Cycle | 2022 | 35240916 | PubTator, text mining | PubMed |
| Research perspectives-Pipelines to human tendon transcriptomics. | J Orthop Res | 2022 | 35239195 | PubTator, text mining | PubMed |
| Analytic approaches to clinical validation of results from preclinical models of glioblastoma: A systematic review. | PLoS One | 2022 | 35231064 | PubTator, text mining | PubMed |
| Sex-specific effects of bisphenol A on the signaling pathway of ESRRG in the human placenta†. | Biol Reprod | 2022 | 35220427 | PubTator, text mining | PubMed |
| Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers. | Cancers (Basel) | 2022 | 35205776 | PubTator, text mining | PubMed |
| Integrated Analysis of Multiple Microarrays Based on Raw Data Identified Novel Gene Signatures in Recurrent Implantation Failure. | Front Endocrinol (Lausanne) | 2022 | 35197930 | PubTator, text mining | PubMed |
| Quercitrin restrains the growth and invasion of lung adenocarcinoma cells by regulating gap junction protein beta 2. | Bioengineered | 2022 | 35196203 | PubTator, text mining | PubMed |
| An in vitro strategy using multiple human induced pluripotent stem cell-derived models to assess the toxicity of chemicals: A case study on paraquat. | Toxicol In Vitro | 2022 | 35182771 | PubTator, text mining | PubMed |
| Comprehensive analysis of the expression and significance of CXCLs in human diffuse large B-cell lymphoma. | Sci Rep | 2022 | 35181719 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9547/papers?page=45